ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Prednisone-Placebo vs Prednisone-Valacyclovir in Bell´s Palsy (PVBP)

This study has been completed.

Sponsored by: Universidad de la Republica
Information provided by: Universidad de la Republica
ClinicalTrials.gov Identifier: NCT00561106
  Purpose

Since steroids carry a moderate beneficial effect in Bell's palsy, and to address this question, valacyclovir was added to prednisone for the treatment of this condition.


Condition Intervention
Bell´s Palsy
Drug: prednisone- valacyclovir
Drug: prednisone-placebo

MedlinePlus related topics:   Bell's Palsy    Benign Tumors    Paralysis   

ChemIDplus related topics:   Valaciclovir    Valacyclovir hydrochloride    Prednisone   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   Treatment Bell´s Palsy: Prednisone vs Prednisone Valacyclovir

Further study details as provided by Universidad de la Republica:

Primary Outcome Measures:
  • The following parameters were used to evaluate the final result: grade of recovery, and sequelae.Facial nerve function was assessed using the facial grading system (FGS) Normal recovery was defined as the return of facial function to FGS 90 or more. [ Time Frame: 6 months ]

Enrollment:   42
Study Start Date:   December 2002
Study Completion Date:   December 2003

Arms Assigned Interventions
1: Active Comparator Drug: prednisone- valacyclovir
prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
2: Placebo Comparator Drug: prednisone-placebo
prednisone, a dose of 1 mg/kg body weight was given daily for 7 days

Detailed Description:

Between December 2002 and December 2003, a total of 52 subjects with BP were evaluated, 42 fulfilled the inclusion criteria and entered the study, 1 patient was lost to follow-up after the first visit, leaving a total of 41 patients with complete clinical follow-up.

To be included in the study, patients had to be evaluated within the first 72 hours and could have no contraindications to steroid or valacyclovir therapy.

Patients were randomly assigned to either the prednisone-valacyclovir (group 1) or the prednisone-placebo group (group 2) Among the 41 patients completing the study, 19 pertenecian al group 1 and 21 group 2 Both groups received prednisone, a dose of 1 mg/kg body weight was given daily for 7 days (one single dose after breakfast). The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days. All subjects were instructed about eye protection and lubrication were followed at regular intervals until recovery or for a minimum period of 3 months. Follow-up included examination at 1, 2, 4, 8 and 12 weeks after the first visit. Patients with incomplete recovery at 3 months were controlled until complete recovery or stabilization of the paralysis. All subjects were evaluated for laboratories parameters. Routine blood count, blood sugar, and liver function tests were performed at first visit.

There were no severe side effects attributable to the valacyclovir-prednisone treatment in this study.

Informed consent was obtained from all patients. Facial nerve function was assessed using the facial grading system (FGS) The scale used provides a quantitative score with three components; resting symmetry, symmetry of voluntary movement and synkinesis and a composite score was obtained.

Student's t-test was employed for quantitative….variables. Comparison of treatment results between both groups was performed by….means of an analysis of variance (ANOVA) test of two ways (therapy and time).

All statistical tests were considered received the same level of significance (P = 0.05).

  Eligibility
Ages Eligible for Study:   14 Years to 82 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients with Bell´s palsy evaluated within the first 72 hours.

Exclusion Criteria:

  • Peptic ulcer
  • Tuberculosis
  • Moderate or severe diabetes
  • Moderate or severe hypertension
  • Glaucoma
  • Manifest cardiac disease
  • Psychosis
  • Renal or hepatic dysfunction, and
  • Pregnancy.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00561106

Locations
Uruguay
Hospital de clinicas    
      Montevideo, Uruguay, 11600

Sponsors and Collaborators
Universidad de la Republica

Investigators
Principal Investigator:     Maria C Vazquez, Dr.     Hospital de Clinicas Facultad de Medicina Universidad de la Republica    
  More Information

Study ID Numbers:   HC 6-8-02
First Received:   November 19, 2007
Last Updated:   November 19, 2007
ClinicalTrials.gov Identifier:   NCT00561106
Health Authority:   Uruguay: Comite de Etica

Keywords provided by Universidad de la Republica:
Bell´s palsy  
prednisone  
valacyclovir  

Study placed in the following topic categories:
Valacyclovir
Mouth Diseases
Virus Diseases
Paralysis
Prednisone
Facies
Facial Nerve Diseases
Bell Palsy
DNA Virus Infections
Stomatognathic Diseases
Bell's palsy
Herpesviridae Infections

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Anti-Infective Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Nervous System Diseases
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Glucocorticoids
Hormones
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Cranial Nerve Diseases

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers